Even in the third quarter, pharmacy and biotechnology were particularly successful

Selected healthcare companies from the APME FX Choice of Excellence list have continued to grow grandiose for the most part in the last quarter. These are medical companies that APME FX broker selected in the study this June as leaders in their industries and companies that signal change and prospects due to the redefinition of values ​​in connection with the Covid-19 pandemic.

In the field of pharmaceutical companies, BioNTech is on the list, biotechnology is represented by REgeneron, medical devices by Medtronic and insurance by the UnitedHealth Group. Except for Medtronic, all companies grew in volume from June 18, 2021 to October 20, 2021.

BionNTech

Current market value of the company (as of October 20, 2021): $65.34 billion. Change from 6/18/2021: + 26.8%

The shares of BioNTech recorded a rapid development during the period under review. By the first decade of August, they initially doubled in value, but then lost sharply, especially during September. The decline was caused by the US FDA regulator approving a booster vaccine against SARS-CoV-2 only for a certain group of people, and by the news that Merck has come up with a promising drug for the treatment of Covid-19.*

Regeneron

Current market value of the company (as of October 20, 2021): $60.18 billion. Change from 6/18/2021: + 4.6%

Regeneron underwent a similar development as BioNTech during the period under review. Its shares strengthened during the summer, then lost. This is also due to the introduction of the Covid medicinal product by Merck. Regeneron has developed a slightly more effective drug for Covid, but much more expensive. The market has assessed that Merck's drug has a better chance of succeeding on the market on a large scale.*

Medtronic

Current market value of the company (as of October 20, 2021): $163.9 billion. Change from 18.6.2021: -1.16%

Although Medtronic performed better than expected in the period under review, the rise of new coronavirus mutations had a negative impact on its business in September. According to Nasdaq.com, the company was losing market share in the diagnosis of cardiovascular disease as well as in the neurovascular business.

UnitedHealth Group

Current market value of the company (as of October 20, 2021): $410.25 billion. Change from 6/18/2021: + 11.8%

Shares of UnitedHealth Group recorded a relatively stable development in the period under review. Only in the second half of September did they begin to lose significantly, but then reached the highest level in their history during October. The positive development in October is mainly due to the announcement of results for the third quarter, which exceeded market expectations.*

 Peter Svoreň, Apme FX

*Past performance is no guarantee of future results.